ACR Convergence 2020

November 5-9, 2020. All Virtual.

View by Number View by Title View Sessions

View by Date

Jump to: [View All] • a b c d e f g h i j k l m n o p q r s t u v w x y z

Abstract Number: 1428

The Efficacy and Safety of Tocilizumab in Patients with Giant Cell Arteritis: A Systematic Review and Meta-Analysis
Abstract Number: 0065

The Energy-dependent Hierarchy of Immune Functions in Human Monocytes
Abstract Number: 0607

The Evolution of Rheumatologist’s Practice in Response to the COVID19 Pandemic
Abstract Number: 1807

The Extent of Tubulointerstitial Inflammation in Lupus Nephritis Identifies Two Distinctive Subgroups: Impact on Inflammation Characteristics and Prognosis in Patients with Lupus Nephritis
Abstract Number: 1499

The Frequency of Contraception Documentation in Women with Lupus and Rheumatoid Arthritis Within the RISE Registry
Abstract Number: 1012

The Global Prevalence of Rheumatoid Arthritis: A Meta-Analysis
Abstract Number: 1100

The Hand Osteoarthritis Registry of New York University: Impacts of Gender and Obesity
Abstract Number: 0921

The Hospital Anxiety and Depression Scale in Patients with Systemic Sclerosis – A Psychometric and Factor Analysis in a Monocentric Cohort
Abstract Number: 0589

The Ideal Mhealth Application for Rheumatoid Arthritis: Qualitative Findings from Stakeholder Focus Groups
Abstract Number: 0979

The Identification of Shared and Unique Myeloid Cell States in Pre- and Post-nephritic Lupus Mouse Models, Sle.Yaa1 and NZBW
Abstract Number: 0350

The Impact of Age and Time Since Diagnosis on Response to Treatment with Secukinumab in Pooled Week 52 Data from 4 Phase 3 Studies in Patients with Ankylosing Spondylitis
Abstract Number: 0575

The Impact of an Integrated Care Management Program on Acute Care Utilization and Outpatient Appointment Attendance Among High-Risk Patients with Lupus
Abstract Number: 1249

The Impact of Anti-Ro Antibodies on the Pregnancy Outcome in Relation to Maternal Disease Presentation: A Descriptive Analysis of 231 Pregnancies
Abstract Number: 1259

The Impact of Antimalarial Agents on Traditional and Non-traditional Cardiovascular Markers in Patients with Systemic Lupus Erythematosus: A Systematic Review and Meta-analysis
Abstract Number: 0685

The Impact of Azathioprine on the Frequency of Persistent Responsiveness to Pegloticase in Patients with Chronic Refractory Gout

Jump to: [View All] • a b c d e f g h i j k l m n o p q r s t u v w x y z

All abstracts accepted to ACR Convergence are under media embargo once the ACR has notified presenters of their abstract’s acceptance. They may be presented at other meetings or published as manuscripts after this time but should not be discussed in non-scholarly venues or outlets. The following embargo policies are strictly enforced by the ACR.

Accepted abstracts are made available to the public online in advance of the meeting and are published in a special online supplement of our scientific journal, Arthritis & Rheumatology. Information contained in those abstracts may not be released until the abstracts appear online. In an exception to the media embargo, academic institutions, private organizations, and companies with products whose value may be influenced by information contained in an abstract may issue a press release to coincide with the availability of an ACR abstract on the ACR website. However, the ACR continues to require that information that goes beyond that contained in the abstract (e.g., discussion of the abstract done as part of editorial news coverage) is under media embargo until 10:00 AM ET on November 14, 2024. Journalists with access to embargoed information cannot release articles or editorial news coverage before this time. Editorial news coverage is considered original articles/videos developed by employed journalists to report facts, commentary, and subject matter expert quotes in a narrative form using a variety of sources (e.g., research, announcements, press releases, events, etc.).

Violation of this policy may result in the abstract being withdrawn from the meeting and other measures deemed appropriate. Authors are responsible for notifying colleagues, institutions, communications firms, and all other stakeholders related to the development or promotion of the abstract about this policy. If you have questions about the ACR abstract embargo policy, please contact ACR abstracts staff at [email protected].